Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation /692/308/153 /631/326/590/1883 perspective

Keyphrases

• Africa 33%
• Brazil 33%
• Clinical Evaluation 100%
• Clinical Trials 33%
• Dosing Regimen 33%
• Flavivirus Vaccine 33%
• Japanese Encephalitis 33%
• Monoclonal Antibody 33%
• Mosquito-borne Flavivirus 33%
• Neutralizing Antibodies 66%
• Neutralizing Antibody Assay 33%
• Nonclinical Development 33%
• Phase 1 Clinical Trial 33%
• Phase 1 Study 33%
• Phase II Clinical Trial 33%
• Public Health Risk 33%
• Reproductive Tissues 33%
• Spectacular 33%
• Tick-borne Encephalitis 33%
• Uganda 33%
• Vaccine Antigen 33%
• Vaccine Candidate 33%
• Vaccine Development 100%
• Virus-neutralizing Antibody 33%
• Whole-cell Vaccine 33%
• Yellow Fever 33%
• Zika Vaccine 100%
• Zika Virus 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Study 25%
• Clinical Trial 100%
• Disease 25%
• Flavivirus 50%
• Immunoassay 25%
• Inactivated Virus Vaccine 25%
• Japanese Encephalitis Vaccine 25%
• Monoclonal Antibody 25%
• Neutralizing Antibody 100%
• Tick Borne Encephalitis 25%
• Vaccine Development 100%
• Yellow Fever 25%
• Zika Virus 75%
• Zika Virus Vaccine 100%

Immunology and Microbiology

• Flavivirus 50%
• Immunoassay 25%
• Inactivated Virus Vaccine 25%
• Japanese Encephalitis Vaccine 25%
• Monoclonal Antibody 25%
• Neutralizing Antibody 100%
• Tick-Borne Encephalitis 25%
• Vaccine Efficacy 75%
• Yellow Fever 25%
• Zika Virus 75%
• Zika Virus Vaccine 100%